论文部分内容阅读
近年,选择性和非选择性的非甾体抗炎药(NSAIDs)安全性一直在被研究和评价。2000年,选择性COX-2抑制剂可能增加严重心血管血栓事件(如心肌梗死或卒中)受到人们关注。2004年,临床试验证明选择性COX-2抑制剂能小幅度增加心血管血栓事件,导致罗非昔布(rofecoxib,万络)主动撤出市场。2005年,选择性COX-2抑制剂被禁用于缺血性心脏疾
In recent years, the safety of selective and nonselective NSAIDs has been investigated and evaluated. In 2000, selective COX-2 inhibitors may increase the risk of serious cardiovascular thrombosis events such as myocardial infarction or stroke. In 2004, clinical trials demonstrated that selective COX-2 inhibitors can slightly increase cardiovascular thromboembolism, leading to the active withdrawal of rofecoxib from the market. In 2005, selective COX-2 inhibitors were banned for ischemic heart disease